Iomeprol

HCID 3731

Grundinformationen

CAS
78649-41-9
Standard-SMILES
CN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
InChIKey
NJKDOADNQSYQEV-UHFFFAOYSA-N
Summenformel
C17H22I3N3O8
Durchschnittliche Molmasse
777,1 g/mol
Monoisotopische Masse
776,8541

Überblick

Iomeprol is a benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position. It has a role as a xenobiotic, a radioopaque medium and an environmental contaminant. It is an organoiodine compound and a benzenedicarboxamide.

Namen und Bezeichner

Bevorzugter Name
Iomeprol
IUPAC
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-methylamino]-2,4,6-triiodobenzene-1,3-dicarboxamide
Englischer Name
IOMEPROL
Summenformel
C17H22I3N3O8
Molmasse
777.09

Namen und Synonyme

iomeprol78649-41-9IomeronIomeprolumIomeproloDTXSID1049061Iomeron 300IOMERVUE-7337N,N'-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(N-methylglycolamido)isophthalamide17E17JBP8LDTXCID2028987
Weitere Namen anzeigen
Iomepol.Iomeron 350ImeronImeron 300Iomeprogr.Iomeprol materialIOMEPROL USP/EP/BPC14348000 Iomeprol
E7337CHEBI:31710N,N'-bis(2,3-dihydroxypropyl)-5-[glycoloyl(methyl)amino]-2,4,6-triiodoisophthalamide1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)methylamino)-2,4,6-triiodo-Iomeprol InjectionN,N'-bis(2,3-dihydroxypropyl)-5-(glycoloyl(methyl)amino)-2,4,6-triiodoisophthalamideRefChem:57671V08AB10

Datenbank-Bezeichner

CAS
78649-41-9
PubChem CID
3731
DTXSID
DTXSID1049061
ChEMBL
CHEMBL2107214
ChEBI
CHEBI:31710
UNII
17E17JBP8L
Nikkaji
J277.762B

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-2,3
Polarare Oberfläche (TPSA)
180 Ų
H-Brücken-Donoren
7
H-Brücken-Akzeptoren
8
Frei drehbare Bindungen
10
Schwere Atome
31

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point285-291
Collision Cross Section221.61 Ų [M+H]+

Physikochemische Eigenschaften

Schmelzpunkt
263 · 263-265C
Siedepunkt
813.2 · 813.2±65.0 °C(Predicted)
Dichte
420 · d420 1.166; d437 1.161; d420 1.334; d437 1.329; d420 1.446; d437 1.441
Brechungsindex
20 · nD20 1.3828; nD20 1.4327; nD20 1.4660
storage temp.
-20 °C · -20°C Freezer
Löslichkeit
DMSO (Slightly), Methanol (Slightly)

Sicherheit und Regulatorisches

Toxikologische Informationen

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

Toxizität
LD50 (400 mgI/ml soln) i.v. in mice, rats (gI/kg): 19.9, 14.5; LD50 (370 mgI/ml soln) i.v. in dogs (gI/kg): >12.5 (Morisetti)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

V08AB10

V - Various

QV - Various

Protein BindingIomeprol does not bind to plasma proteins.
Pharmacodynamics · 1 Eintrag

The degree of radiographic enhancement by iomeprol is related to the iodine concentration in the tissue of interest following the administration of iomeprol. However, the exposure-response relationships and time course of pharmacodynamic response of iomeprol have not been fully characterized. At therapeutic concentrations, iomeprol was not shown to cause significant effects on the cardiovascular, central nervous, renal, and complement systems.

Mechanism of Action · 1 Eintrag

Iomeprol is a radiographic iodinated contrast agent that opacifies the vessels and body structures where the contrast agent is present following intravenous or intra-arterial administration, permitting radiographic visualization of the internal structures through attenuation of X-ray photons. In imaging of the body, iodinated contrast agents diffuse from the vessels into the extravascular space. In normal brain with an intact blood-brain barrier, the contrast agent does not diffuse into the extravascular space and contrast enhancement is generally due to the presence of contrast within the vascular space. In patients with a disrupted blood-brain barrier, the contrast agent accumulates in the extravascular space in the region of disruption.

Biological Half-LifeThe elimination half-life of iomeprol is 1.8 (0.33) hours.
Metabolism/MetabolitesIomeprol does not undergo significant metabolism.

Verwendung und Herstellung

UsesUse (kg) in Switzerland (2009): >1000

Anbieter74 Anbieter

天津欣康佑生物科技有限公司19922659386 · [email protected]
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.+86-18600796368 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]
江苏艾康生物医药研发有限公司025-58851090 19370895928 · [email protected]
湖北海克斯生化有限公司17362916295; 17362916295 · [email protected]

Ergänzende Hinweise

DefinitionChEBI: A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position.

Zugehörige Reaktionen

0

Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.

Notizen zur Verbindung

Wird geladen…